Alaunos Therapeutics, Inc.

Equities

TCRT

US98973P2002

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 04:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
1.27 ^USD	+2.42%		-3.79%	+19.75%

Apr. 01	Alaunos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 05	North American Morning Briefing : S&P 500 Futures -2-	DJ

Alaunos Therapeutics, Inc. Announces Resignation of Christopher Bowden as Board of Directors

March 30, 2023 at 07:42 am EDT

Alaunos Therapeutics, Inc. announced on March 29, 2023, Christopher Bowden, M.D. delivered notice of his resignation from the board of directors of the company, effective March 30, 2023. Dr. Bowden's resignation from the Board did not result from any disagreement with the company.

Latest news about Alaunos Therapeutics, Inc.

Alaunos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
North American Morning Briefing : S&P 500 Futures -2-	Mar. 05	DJ
Alaunos Therapeutics, Inc. Appoints Dale Curtis Hogue, Jr. as Interim Chief Executive Officer	Jan. 22	CI
Alaunos Therapeutics, Inc. Appoints Dale Curtis Hogue as Director	Jan. 02	CI
Alaunos Therapeutics, Inc. Announces the Resignation of Mary Thistle as Member of the Board of Directors	Dec. 22	CI
Alaunos Therapeutics, Inc.(NasdaqCM:TCRT) dropped from S&P Global BMI Index	Dec. 18	CI
Alaunos Therapeutics, Inc.(NasdaqCM:TCRT) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Alaunos Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
North American Morning Briefing : Stock Futures Dip as Inflation Data Looms	Nov. 13	DJ
Alaunos Therapeutics, Inc. Announces Board Changes	23-09-28	CI
North American Morning Briefing : Focus Shifts to Jackson Hole Later This Week	23-08-21	DJ
North American Morning Briefing : Treasury Yields -2-	23-08-17	DJ
HC Wainwright Downgrades Alaunos Therapeutics to Neutral From Buy	23-08-16	MT
North American Morning Briefing : Stock Futures -2-	23-08-16	DJ
Laidlaw Downgrades Alaunos Therapeutics to Hold From Buy	23-08-15	MT
Sector Update: Health Care Stocks Slip Pre-Bell Tuesday	23-08-15	MT
Alaunos Therapeutics to Cut Staff by 60%; Considering Strategic Alternatives; Shares Plummet Pre-Bell	23-08-15	MT
Alaunos Therapeutics to Cut Workforce by Roughly 60%	23-08-15	MT
Alaunos Therapeutics Announces Exploration of Strategic Alternatives	23-08-14	CI
Alaunos Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2023	23-08-14	CI
North American Morning Briefing : Stock Futures Firmer Despite More China Stress	23-08-14	DJ
Alaunos Therapeutics Announces Presentation At the 2Nd Hawaii Global Summit on Thoracic Malignancies	23-06-29	CI
Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting	23-05-25	CI
Transcript : Alaunos Therapeutics, Inc., Q1 2023 Earnings Call, May 10, 2023	23-05-10
Alaunos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI

Chart Alaunos Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. The Company is focused on exploring strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. Separately, the Company is evaluating several potential in-licensing opportunities in obesity, oncology and virology.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.27

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ALAUNOS THERAPEUTICS, INC.	+19.75%	20.34M
VERTEX PHARMACEUTICALS INCORPORATED	+5.66%	111B
REGENERON PHARMACEUTICALS, INC.	+11.23%	105B
BIONTECH SE	-12.15%	22.34B
ARGENX SE	-3.38%	21.93B
GENMAB A/S	-6.17%	18.59B
WUXI APPTEC CO., LTD.	-36.52%	18.12B
BEIGENE, LTD.	-10.09%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+3.33%	13.7B
SAREPTA THERAPEUTICS, INC.	+36.58%	12.45B

Bio Therapeutic Drugs